IL6 and Alzheimer disease: Since the decline in PHA-lymphoproliferation and the high release of IL-6 after LPS stimulation not only occur in severe AD patients but also begin to decline in mAD patients, this suggests that both parameters could be used as possible early peripheral biomarkers of AD.